Scalable Green Synthesis and Full-Scale Test of the Metal-Organic Framework CAU-10-H for Use in Adsorption-Driven Chillers.

The demand for cooling devices has increased during the last years and this trend will continue. Adsorption-driven chillers (ADCs) using water as the working fluid and low temperature waste energy for regeneration are an environmentally friendly alternative to currently employed cooling devices and can concurrently help to dramatically decrease energy consumption. Due to the ideal water sorption behavior and proven lifetime stability of [Al(OH)(m-BDC)] ∙ x H O (m-BDC = 1,3-benzenedicarboxylate), also denoted CAU-10-H, a green very robust synthesis process under reflux, with high yields up to 95% is developed and scaled up to 12 kg-scale.

Synthesis of M-UiO-66 (M = Zr, Ce or Hf) employing 2,5-pyridinedicarboxylic acid as a linker: defect chemistry, framework hydrophilisation and sorption properties.

Metal-organic frameworks of general composition [M(OH)(O)(PDC)(Cl)(HO)] with M = Zr, Ce, Hf; PDC = 2,5-pyridinedicarboxylate and 0 ≤ x ≤ 2 were obtained under reflux using formic, nitric or acetic acid as an additive. Rietveld refinements carried out using a fixed occupancy of the linker molecules according to the results of thermogravimetric measurements confirmed that the MOFs crystallize in the UiO-66 type structure and demonstrate that the structural models describe the data well. Further characterization was carried out by NMR spectroscopy, thermogravimetric analysis, Zr K-edge EXAFS- and Ce L-edge XANES measurements.

A New Ethical Challenge for Institutional Review Boards (IRBs)/Ethics Committees (ECs) in the Assessment of Pediatric Clinical Trials.

Both the US and EU have introduced pediatric pharmaceutical legislation to facilitate clinical trials in children and development of better medicines for children. The first concerns were published in 2014 that the European Medicines Agency (EMA)'s Pediatric Committee (PDCO) may be over-enthusiastic and has compelled questionable pediatric clinical trials from pharmaceutical companies. Numerous clinical trials are mandated in rare conditions for which not enough patients exist for even one trial.